Toronto Innovation Acceleration Partners

What Toronto Innovation Acceleration Partners does

Toronto Innovation Acceleration Partners (TIAP) is a Toronto-based, member-supported not-for-profit organization founded in 2008 (originally as MaRS Innovation) that identifies, funds, and develops early-stage health science innovations from nine Toronto academic member institutions into commercial Canadian ventures. Its member institutions include CAMH, MaRS, OICR, SickKids, Sinai Health, Sunnybrook, Unity Health, UHN, and the University of Toronto. TIAP's portfolio is focused exclusively on therapeutics, medical devices, and digital health, and it has helped launch more than 70 companies that have collectively raised over $1 billion in private investment and created more than 1,000 jobs.

TIAP operates a platform of interconnected programs rather than a single product: LAB150-NextGen provides up to $1.6M USD in milestone-based drug development funding partnered with pharma-grade CROs; UTEST (co-managed with the University of Toronto) provides entrepreneurship training, in-kind legal services, and pre-seed investment for medical device and digital health ventures; Venture Builder supports company formation, C-suite access, and seed financing; the Critical Technologies Initiative provides up to $200K for emerging life sciences technologies using AI, quantum, blockchain, robotics, and cybersecurity; and Portfolio Management provides follow-on financing and business development support. Strategic industry partnerships with Amgen and Evotec SE underpin the LAB150 program, and government funding has historically flowed through the CECR program and FedDev Ontario.

TIAP's business model is that of a not-for-profit venture builder: it does not generate revenue from product sales and does not charge fees to researchers for initial program access. Operating funds come from government grants (notably a $3.5M FedDev Ontario investment in February 2025 supporting 50 health sciences businesses), strategic industry partner contributions, member institution support, and returns on portfolio investments. Programs deliver milestone-based grants and equity investments rather than paid services. The organization is headquartered at the MaRS Centre in Toronto's Discovery District, employs 11-50 people, and is governed by a Board chaired by Angus J. Grant (former EVP, Teva Pharmaceutical Industries), with member-institution and independent director representation. In April 2026, Prakash Gowd assumed the role of Interim President and CEO following Parimal Nathwani's transition to BDC Capital.

Name

Toronto Innovation Acceleration Partners

Legal name

Toronto Innovation Acceleration Partners

Website

https://tiap.ca/

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

11–50 employees

Short description

Toronto Innovation Acceleration Partners is a Toronto-based not-for-profit venture builder that identifies, funds, and commercializes early-stage health science innovations from nine member academic institutions, running programs such as LAB150-NextGen, UTEST, Venture Builder, and Critical Technologies across therapeutics, medical devices, and digital health.

Ownership category

akta.pro rank

Product category

Health Sciences Venture Building

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Other Scientific and Technical Consulting Services (54169)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Management Consulting Services (8742)

akta.pro primary industry

Corporate Venture Studios & Incubators (Build/launch ventures) (FSANAHAC)

akta.pro secondary industries

Corporate Deep Tech / R&D Commercialization CVC (FSANAHAL), Joint Venture CVC / Consortium Funds (Multi-corporate) (FSANAHAE)

Keywords

• Health science venture building
• Academic technology commercialization
• Early-stage life sciences funding
• Biotech pre-seed investment
• Medical device incubation

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Venture Building and Program Management: TIAP operates as a not-for-profit organization funded by government grants (FedDev Ontario, CECR program), strategic industry partnerships (Amgen, Evotec SE), and member institution contributions. Revenue is not generated from product sales but from program delivery, investment returns, and funding partnerships that support commercialization of member innovations.

Distribution channels2 records

Marketing channels5 records

Core offering

Toronto Innovation Acceleration Partners (TIAP) is a member-driven, not-for-profit venture builder that identifies, funds, and develops transformative early-stage health science innovations from Toronto's leading academic and hospital member institutions into successful Canadian companies. It operates programs spanning drug development (LAB150-NextGen), medical device and digital health (UTEST), venture formation (Venture Builder), follow-on financing (Portfolio Management), and emerging technology funding (Critical Technologies Initiative).

Product overview

TIAP is a not-for-profit venture-building organization that transforms early-stage health science innovations from academic member institutions into successful Canadian commercial ventures. Rather than a single unified software product, TIAP operates a platform of interconnected programs: LAB150-NextGen provides milestone-based drug development funding; UTEST supports medical device and digital health ventures; Venture Builder assists with company formation and seed financing; Portfolio Management offers follow-on support and business development; and the Critical Technologies Initiative funds emerging technologies in AI, quantum computing, robotics, and cybersecurity. TIAP's portfolio spans therapeutics, medical devices, and digital health/AI across 70+ companies that have collectively raised over $1 billion. The organization also partners with Mission BioCapital to provide international resources to Canadian biotech startups.

Differentiator

Problem solved

Functional benefit

Products and services

• LAB150-NextGen A drug development program that supports advancement and commercialization of research projects from TIAP member institutions, offering up to $1.6M USD in milestone-based funding split between academic labs and pharma-grade CROs, with the twin goals of developing new drug candidates and launching Ontario-based biotechnology companies.
• UTEST (University of Toronto Early-Stage Technology) A program for medical device and digital health/AI ventures, co-managed with the University of Toronto, providing entrepreneurship training, in-kind legal services, pre-seed investment, and access to a network of investors.
• Venture Builder A program focused on technology and business plan development, access to qualified C-suite management, third-party financial and strategic investors, incorporation and in-licensing of technology, and seed financing.
• Portfolio Management A program providing follow-on and bridge financing, a network of experts for board and leadership roles, business development with strategic and financial investors, and support for emerging life sciences technologies.
• Critical Technologies Initiative A funding program providing up to $200K (grant up to $100K plus dilutive match) for emerging life sciences technologies and early-stage ventures utilizing 5G, blockchain, cybersecurity, ethical AI, quantum computing, and/or robotics. Delivered in partnership with OBIO's Life Sciences Critical Technologies & Commercialization Centre of Excellence.
• Mission BioCapital Platinum Program Partnership A partnership bringing Mission BioCapital's Platinum Program to Canada's leading health sciences cluster, providing up to $500K in pre-seed capital, guaranteed lab space at BioLabs University of Toronto, and mentorship from Mission BioCapital and industry partners to biotech start-ups.

Quantifiable outcome

• 70+ companies launched and $1B+ raised by portfolio companies
• +2 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Four partnerships are on record, tiered core.

• Mission BioCapitalcoreStrategic or Co-development Partner · 2 April 2026TIAP has entered into a new partnership with Mission BioCapital to bring dedicated support from their Platinum Program to biotech start-ups in Canada's leading health sciences cluster. For 2026, the program awards up to eight Platinum Tickets to high-potential companies, including up to two for Toronto/Canada, providing up to $500K in pre-seed capital, guaranteed lab space at BioLabs University of Toronto, and mentorship. TIAP is a sponsor providing capital as part of the pre-seed funding pool.
• MaRS Discovery DistrictcoreStrategic or Co-development Partner · 27 October 2025Joint launch of Life Sciences Central initiative with OBIO and TIAP. This collaborative initiative consolidates commercialization services, investment networks, and talent resources to help Ontario health and life sciences startups scale faster, raise critical early-stage funding, and remain rooted in Ontario.
• OBIOcoreStrategic or Co-development Partner · 27 October 2025Joint launch of Life Sciences Central initiative alongside MaRS and TIAP. OBIO also partners with TIAP on the Critical Technologies Program and the Life Sciences Critical Technologies & Commercialization (LSCTC) Centre of Excellence, providing funding and support for emerging life sciences technologies.
• Evotec SEcoreStrategic or Co-development Partner · 1 January 2008Global pharmaceutical company partnering through TIAP's LAB150 program for drug discovery and development. Evotec provides pharma-grade contract research organization (CRO) capabilities and expertise for milestone-based drug development projects.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• adMare BioInnovations: Canada's largest life-sciences venture builder, headquartered in Montreal with a pan-Canadian mandate. adMare builds and invests in therapeutic companies from academic research, operating a similar translational venture-builder model to TIAP but at a national scale and with a private (not not-for-profit) corporate structure.
• OBIO (Ontario Bioscience Innovation Organization): Ontario's health-science industry association and commercialization partner. OBIO co-launches initiatives with TIAP (Life Sciences Central, LSCTC Centre of Excellence, Critical Technologies Program) and operates overlapping programs supporting early-stage health-science ventures in Ontario, including the OBIO Critical Technologies and Early-Stage Health-tech streams.
• CQDM (Consortium Québécois sur la Découverte du Médicament): Quebec-based biopharmaceutical research consortium that funds and accelerates drug discovery projects through partnerships between academia and pharma. CQDM mirrors TIAP's LAB150 model of co-funding academic drug discovery with pharma partners (Pfizer, AstraZeneca, Merck, etc.).
• Accel-Rx Health Sciences Catalyst: Vancouver-based Canadian health-sciences accelerator that provides seed funding, mentorship, and connections for early-stage therapeutics, medical devices, and digital health ventures. Accel-Rx pursues a comparable pan-Canadian health-science venture-building thesis to TIAP.
• Mission BioCapital: U.S.-focused biotech venture firm that operates the Platinum Program providing pre-seed capital, lab space at BioLabs, and mentorship to early-stage biotech startups. Mission BioCapital is now a direct TIAP partner, making it the closest cross-border peer for TIAP's venture-builder model.

Broad incumbents

• Creative Destruction Lab (CDL): Toronto-based (Rotman School) venture-building program for science-based startups across multiple sectors including health. CDL operates a broader, multi-stream program (not health-only) but shares TIAP's Toronto roots, academic-spinout orientation, and objective-setting venture-builder methodology.
• MaRS Discovery District: Toronto's largest urban innovation hub, physically hosting TIAP's headquarters. MaRS supports health-science and other sector startups through incubation, advisory, and capital networks, and is a direct co-launch partner of TIAP's Life Sciences Central initiative.
• BDC Capital Life Sciences Venture Fund: Canada's largest VC arm with a dedicated Life Sciences fund that invests in Canadian health-science companies. Notably, former TIAP CEO Parimal Nathwani now runs this fund, making it both a downstream capital provider to TIAP's portfolio and a potential competitor for the same deal flow.

Regional players

• BioEnterprise Corporation: U.S. Midwest-focused health-sciences venture accelerator that provides commercialization support and capital formation to health-tech and bio entrepreneurs. Comparable regional venture-builder model focused on health sciences, but operating in a different geography than TIAP's Canadian mandate.
• FutuRx: Israeli biotech incubator backed by pharma partners (Johnson & Johnson, Roche, Pfizer, Takeda) that operates an academic-sourced drug discovery model structurally similar to TIAP's LAB150 program. Relevant peer because TIAP's Director Ido Kaminsky previously served as Director of Business Analysis at FutuRx.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xtwitter.com/TIAPToronto
• LinkedInlinkedin.com/company/mars-innovation

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments87 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Toronto Innovation Acceleration Partners